Drug intelligence / Profile preview

OCN-108

Development stage: Preclinical
Lead developer: Onconic Therapeutics

Overview

OCN-108 is an investigational drug candidate currently in the preclinical stage of development by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical. It is being developed for the treatment of solid tumors. As of the current development cycle, the specific molecular target, modality, and mechanism of action for OCN-108 have not been publicly disclosed. The asset is part of Onconic's oncology pipeline, which aims to develop next-generation targeted therapies for various cancer indications.

Beyond the preview

Go deeper on OCN-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCN-108.

Explore the full profile